Patents by Inventor John A. Butera

John A. Butera has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED LYSINE-MIMETIC COMPOUNDS
    Publication number: 20120245106
    Abstract: Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable bioavailability properties are disclosed.
    Type: Application
    Filed: September 16, 2011
    Publication date: September 27, 2012
    Applicant: Zealand Pharma A/S
    Inventors: Bjarne Due Larsen, Jørgen Søberg Petersen, Ketil Jørgen Haugan, John A. Butera, James K. Hennan, Edward H. Kerns, Evgueni Lvovich Piatnitski
  • Modified lysine-mimetic compounds
    Patent number: 8026272
    Abstract: Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable bioavailability properties are disclosed.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: September 27, 2011
    Assignee: Zealand Pharma A/S
    Inventors: Bjarne Due Larsen, Jørgen Søberg Petersen, Ketil Jørgen Haugan, John A. Butera, James K. Hennan, Edward H. Kerns, Evgueni Lvovich Piatnitski
  • Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and methods of use thereof
    Patent number: 7879825
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided where at least one of R2 or R3 is not hydrogen. The compounds of the present invention are N-methyl-D-aspartate (NMDA) receptor antagonists and are useful in treating a variety of conditions present in a mammal that benefit from inhibiting the NMDA receptor.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: February 1, 2011
    Assignee: Wyeth LLC
    Inventors: Reinhardt B. Baudy, John A. Butera
  • MODIFIED LYSINE-MIMETIC COMPOUNDS
    Publication number: 20100249206
    Abstract: Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable bioavailability properties are disclosed.
    Type: Application
    Filed: October 30, 2009
    Publication date: September 30, 2010
    Inventors: Bjarne Due Larsen, Jorgen Soberg Petersen, Ketil Jorgen Haugan, John A. Butera, James K. Hennan, Edward H. Kerns, Evgueni Lvovich Piatnitski
  • Tetracyclic indoles as potassium channel modulators
    Patent number: 7662831
    Abstract: The present invention is directed to compounds of Formula I: that are potassium channel modulators and pharmaceutical compositions thereof. The present invention is further directed to methods of treatment using the compounds and pharmaceutical compositions of the invention. The present invention is still further directed to synthetic processes for producing the compounds of the invention.
    Type: Grant
    Filed: July 26, 2007
    Date of Patent: February 16, 2010
    Assignee: Wyeth LLC
    Inventors: Matthew A. Wilson, Gregory S. Welmaker, Eugene J. Trybulski, John A. Butera, Ronald L. Magolda
  • Modified lysine-mimetic compounds
    Patent number: 7622496
    Abstract: Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable bioavailability properties are disclosed.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: November 24, 2009
    Assignees: Zealand Pharma A/S, Wyeth
    Inventors: Bjarne Due Larsen, Jørgen Søberg Petersen, Ketil Jørgen Haugan, John A. Butera, James K. Hennan, Edward H. Kerns, Evgueni L. Piatnitski
  • Benzofurans as potassium ion channel modulators
    Patent number: 7601856
    Abstract: The present invention is directed to compounds of Formula I: that are potassium channel modulators and pharmaceutical compositions thereof. The present invention is further directed to methods of treatment using the compounds and pharmaceutical compositions of the invention. The present invention is still further directed to synthetic processes for producing the compounds of the invention.
    Type: Grant
    Filed: July 26, 2007
    Date of Patent: October 13, 2009
    Assignee: Wyeth
    Inventors: Gregory S. Welmaker, Matthew A. Wilson, Geraldine McFarlane, Joan E. Sabalski, John A. Butera, Eugene J. Trybulski, David R. Herbst
  • TETRACYCLIC INDOLES AS POTASSIUM CHANNEL MODULATORS
    Publication number: 20080027090
    Abstract: The present invention is directed to compounds of Formula I: that are potassium channel modulators and pharmaceutical compositions thereof. The present invention is further directed to methods of treatment using the compounds and pharmaceutical compositions of the invention. The present invention is still further directed to synthetic processes for producing the compounds of the invention.
    Type: Application
    Filed: July 26, 2007
    Publication date: January 31, 2008
    Applicant: WYETH
    Inventors: Matthew A. WILSON, Gregory S. WELMAKER, Eugene J. Trybulski, John A. BUTERA, Ronald L. MAGOLDA
  • BENZOFURANS AS POTASSIUM ION CHANNEL MODULATORS
    Publication number: 20080027049
    Abstract: The present invention is directed to compounds of Formula I: that are potassium channel modulators and pharmaceutical compositions thereof. The present invention is further directed to methods of treatment using the compounds and pharmaceutical compositions of the invention. The present invention is still further directed to synthetic processes for producing the compounds of the invention.
    Type: Application
    Filed: July 26, 2007
    Publication date: January 31, 2008
    Applicant: WYETH
    Inventors: Gregory S. WELMAKER, Matthew A. WILSON, Geraldine R. McFARLANE, Joan E. SABALSKI, John A. BUTERA, Eugene J. Trybulski, David R. HERBST
  • Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] Phosphonic Acid and Methods of Use Thereof
    Publication number: 20070225257
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided where at least one of R2 or R3 is not hydrogen. The compounds of the present invention are N-methyl-D-aspartate (NMDA) receptor antagonists and are useful in treating a variety of conditions present in a mammal that benefit from inhibiting the NMDA receptor.
    Type: Application
    Filed: June 1, 2007
    Publication date: September 27, 2007
    Applicant: Wyeth
    Inventors: Reinhardt Baudy, John Butera
  • Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and methods of use thereof
    Patent number: 7253153
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided where at least one of R2 or R3 is not hydrogen. The compounds of the present invention are N-methyl-D-aspartate (NMDA) receptor antagonists and are useful in treating a variety of conditions present in a mammal that benefit from inhibiting the NMDA receptor.
    Type: Grant
    Filed: April 7, 2004
    Date of Patent: August 7, 2007
    Assignee: Wyeth
    Inventors: Reinhardt B. Baudy, John A. Butera
  • Modified lysine-mimetic compounds
    Publication number: 20070149460
    Abstract: Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable bioavailability properties are disclosed.
    Type: Application
    Filed: December 21, 2006
    Publication date: June 28, 2007
    Inventors: Bjarne Larsen, Jorgen Petersen, Ketil Haugan, John Butera, James Hennan, Edward Kerns, Evgueni Piatnitski
  • 1,3-disubstituted-2-thioxo-imidazolidine-4,5-diones as potassium channel openers
    Patent number: 7115620
    Abstract: Compounds of Formula I are provided: wherein: R is lower alkyl or branched lower alkyl; and Ar is phenyl, phenyl substituted with one or more of halogen, lower alkyl, lower alkoxy, lower alkylthio, lower alkylamino, cyano, or perfluoroalkoxy, or a heteroaromatic moiety; and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: October 29, 2002
    Date of Patent: October 3, 2006
    Assignee: Wyeth
    Inventors: John A Butera, Hassan M Elokdah, Theodore S Sulkowski, John L Primeau, Joseph R Lennox, Russell F Graceffa
  • 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
    Patent number: 7008636
    Abstract: This invention provides compounds of Formula I having the structure or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.
    Type: Grant
    Filed: May 11, 2004
    Date of Patent: March 7, 2006
    Assignee: Wyeth
    Inventors: John A. Butera, Craig E. Caufield, Russell F. Graceffa, Alexander Greenfield, Eric G. Gundersen, Lisa Marie Havran, Alan H. Katz, Joseph R. Lennox, Scott C. Mayer, Robert E. McDevitt
  • Substituted benzofuran oximes
    Publication number: 20050215626
    Abstract: The present invention relates to substituted benzofuran oximes and methods of using them.
    Type: Application
    Filed: September 23, 2004
    Publication date: September 29, 2005
    Applicant: WYETH
    Inventors: Lisa Havran, John Butera, Hassan Elokdah, Douglas Jenkins, Eric Gundersen
  • Substituted aryloximes
    Publication number: 20050119326
    Abstract: The present invention relates to substituted indole oximes and methods of using them.
    Type: Application
    Filed: September 23, 2004
    Publication date: June 2, 2005
    Applicant: WYETH
    Inventors: Lisa Havran, John Butera, Hassan Elokdah, Douglas Jenkins, Eric Gundersen
  • Substituted aryloximes
    Publication number: 20050070584
    Abstract: The present invention relates to substituted aryl oximes and methods of using them.
    Type: Application
    Filed: September 23, 2004
    Publication date: March 31, 2005
    Applicant: WYETH
    Inventors: Lisa Havran, John Butera, Hassan Elokdah, Douglas Jenkins, Eric Gundersen
  • 3-Amino chroman and 2-amino tetralin derivatives
    Publication number: 20050032873
    Abstract: 3-Amino chroman and 2-amino tetralin derivatives and compositions containing such compounds are disclosed. Methods of using the 3-amino chroman and 2-amino tetralin compounds and compositions containing such compounds in the treatment of serotonin disorders, such as depression and anxiety, are also disclosed.
    Type: Application
    Filed: July 26, 2004
    Publication date: February 10, 2005
    Applicant: Wyeth
    Inventors: Nicole Hatzenbuhler, Deborah Evrard, Richard Mewshaw, Dahui Zhou, Uresh Shah, Jennifer Inghrim, Steven Lenicek, Reinhardt Baudy, John Butera, Annmarie Sabb, Amedeo Failli, Pudukkaraipudur Ramamoorthy
  • Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and methods of use thereof
    Publication number: 20050004080
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided where at least one of R2 or R3 is not hydrogen. The compounds of the present invention are N-methyl-D-aspartate (NMDA) receptor antagonists and are useful in treating a variety of conditions present in a mammal that benefit from inhibiting the NMDA receptor.
    Type: Application
    Filed: April 7, 2004
    Publication date: January 6, 2005
    Applicant: Wyeth
    Inventors: Reinhardt Baudy, John Butera
  • 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
    Publication number: 20040214869
    Abstract: This invention provides compounds of Formula I having the structure 1
    Type: Application
    Filed: May 11, 2004
    Publication date: October 28, 2004
    Applicant: Wyeth
    Inventors: John A. Butera, Craig E. Caufield, Russell F. Graceffa, Alexander Greenfield, Eric G. Gundersen, Lisa Marie Havran, Alan H. Katz, Joseph R. Lennox, Scott C. Mayer, Robert E. McDevitt